Sorrento Therapeutics downgraded to Neutral from Buy at Dawson James
PremiumThe FlySorrento Therapeutics downgraded to Neutral from Buy at Dawson James
2y ago
Sorrento Therapeutics files for Chapter 11 bankruptcy in Texas
Premium
The Fly
Sorrento Therapeutics files for Chapter 11 bankruptcy in Texas
2y ago
Scilex acquires rights to FDA-approved ELYXYB in U.S., Canada
Premium
The Fly
Scilex acquires rights to FDA-approved ELYXYB in U.S., Canada
2y ago
Sorrento Therapeutics receives FDA clearance to initial trials with STI-1557
PremiumThe FlySorrento Therapeutics receives FDA clearance to initial trials with STI-1557
2y ago
Sorrento presents Phase 2 results on PD-L1 checkpoint inhibitor IMC-001
Premium
The Fly
Sorrento presents Phase 2 results on PD-L1 checkpoint inhibitor IMC-001
2y ago
Sorrento reports safety and pharmacokinetic data from Phase I study of STI-1558
Premium
The Fly
Sorrento reports safety and pharmacokinetic data from Phase I study of STI-1558
2y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100